[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"JIANYANG WANG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100595840","phase-2-radiotherapy-plus-anlotinib-in-la-nsclc-intolerable-to-ccrt-100595840",false,"NCT07037680","Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT","Efficiency and Safety of Radiotherapy Combined With Anlotinib in Locally Advanced Non-small Cell Lung Cancer Patients Intolerable to Concurrent Chemoradiotherapy: A Phase II Single-arm Trial","Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK\u002FROS1-mutated locally advanced unresectable NSCLC were screened.\n\nInclusion Criteria:\n\n1. ≥18 years old with no restrictions on sex;\n2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;\n3. Eastern cooperative oncology group (ECOG) score ≤2 was required;\n4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;\n5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;\n6. No symptoms of hemoptysis;\n7. Adequate hepatic and renal functions with a negative urine protein;\n8. Expected survival of more than 6 months.\n\nExclusion Criteria:\n\n1. currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;\n2. previous malignancy within five years;\n3. thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;\n4. uncontrolled or active pulmonary inflammation;\n5. participated in other clinical trials;\n6. Pregnant women.","ALL","18 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.",[26,27,28],"Locally Advanced Non-Small Cell Lung Cancer","Thoracic Radiotherapy","Safety",[30,31,32,33,34],"thoracic radiotherapy","non-small cell lung carcinoma","locally advanced","safety","Anlotinib","RECRUITING","2025-07-03",{"date":38,"type":39},"2025-07-09","ACTUAL",{"date":41,"type":39},"2024-01-01",{"date":43,"type":20},"2026-06-30",{"name":45,"class":46},"JIANYANG WANG","OTHER",""]